Literature DB >> 6364807

Therapy for acute pelvic inflammatory disease: a critique of recent treatment trials.

R C Brunham.   

Abstract

Recent approaches to determine optimal antimicrobial treatment for acute pelvic inflammatory disease are reviewed. From this review, it is suggested that in future studies a randomized study design, with controls for known factors which influence prognosis, and a uniform objective scoring system for monitoring clinical response be used and long-term evaluation of tubal function be performed. Such studies are urgently needed if optimal therapy for pelvic inflammatory disease is to be defined.

Mesh:

Substances:

Year:  1984        PMID: 6364807     DOI: 10.1016/s0002-9378(84)80061-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

Review 1.  Optimum therapy for acute pelvic inflammatory disease.

Authors:  M G Dodson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

2.  Treating pelvic inflammatory disease with doxycycline and metronidazole or penicillin and metronidazole.

Authors:  P K Heinonen; K Teisala; R Punnonen; R Aine; M Lehtinen; A Miettinen; J Paavonen
Journal:  Genitourin Med       Date:  1986-08

Review 3.  Pelvic inflammatory disease: current concepts and treatment guidelines.

Authors:  P A Dale; P A Rice; K C Edelin
Journal:  J Gen Intern Med       Date:  1986 Nov-Dec       Impact factor: 5.128

Review 4.  Role of cephalosporins in gonorrhoea and other sexually transmitted diseases.

Authors:  I Phillips
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 5.  Tubo-ovarian abscess: pathogenesis and management.

Authors:  N G Osborne
Journal:  J Natl Med Assoc       Date:  1986-10       Impact factor: 1.798

6.  Treatment of acute pelvic inflammatory disease in the ambulatory setting: trial of cefoxitin and doxycycline versus ampicillin-sulbactam.

Authors:  M Kosseim; A Ronald; F A Plummer; L D'Costa; R C Brunham
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

Review 7.  Beta-lactams in sexually transmitted diseases: rationale for selection and dosing regimens.

Authors:  D Kunimoto; R Brunham; A Ronald
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

Review 8.  Quinolones in sexually transmitted diseases. Global experience.

Authors:  G L Ridgway
Journal:  Drugs       Date:  1995       Impact factor: 9.546

9.  Sulbactam/ampicillin versus cefoxitin for uncomplicated and complicated acute pelvic inflammatory disease.

Authors:  D L Hemsell; M C Heard; P G Hemsell; B J Nobles
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.